Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

Matti Aapro, Paul Cornes, Ivo Abraham

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Fingerprint Dive into the research topics of 'Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia'. Together they form a unique fingerprint.

Medicine & Life Sciences